Compare Inovio Pharmaceuticals Inc (INO) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Verisign, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $90.50M), while Verisign, Inc. trades at $262.86 (market cap $24.22B). The key difference: Verisign, Inc. is far larger — about 267.6× Inovio Pharmaceuticals Inc's market cap, and Verisign, Inc. pays a 1.22% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | VRSN | |
|---|---|---|
Market Cap | $90.50M | $24.22B |
Sector | Health | Technology |
52-Week High | $2.87 | $310.00 |
52-Week Low | $1.05 | $211.49 |
Enterprise Value | $61.51M | $25.46B |
Dividend Yield | — | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
VeriSign (VRSN) trades at $266.15, down 4.15% over the past day, with a mixed technical outlook showing bullish moving averages but overbought oscillators. The company maintains strong fundamentals with 2025 revenue of $1.66 billion, net income of $825.7 million, and a robust net income margin of 49.96%. Recent Q1 2026 earnings beat expectations with EPS of $2.34, while Q2 2026 results are anticipated. Analyst sentiment is predominantly positive with a 57% buy rating and a consensus price target of $325.25, suggesting significant upside potential.
The outlook for VRSN is cautiously optimistic, driven by its monopoly position in .com and .net domain registrations, consistent cash flow generation, and potential tailwinds from AI-driven domain growth. Key risks include contract renewal uncertainties, competitive pressures, and high valuation multiples. Investors should weigh the stock's premium valuation against its stable revenue streams and growth catalysts from digital expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
